STOCK ALARMSA

Demo Log In

Personalis, Inc.(PSNL)

$17.31—

Chart

Personalis, Inc.(PSNL)

NASDAQ

$17.31—

Chart Studio

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

8/25/26

PERSONALIS (PSNL)

Tuesday

2:04 PM

Thesis: The recent strategic partnerships and technological advancements are expected to significantly enhance revenue potential and market positioning.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$70M	$81M	$110M
Rev. Growth	-17.7%	+16.8%	+35.2%
EPS	$-0.91	$-1.08	$-0.94
EPS Growth	+33.6%	-18.6%	+13.0%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $110M — +35.2% growth in a single year.

Why Revenue Could Accelerate

1Recent partnership with a leading pharmaceutical company to develop a new genomic test for cancer treatment could increase revenue by 25% over the next year.
2Expansion into European markets is expected to drive a 30% increase in test volume by the end of FY26.
3Development of a new AI-driven genomic analysis tool that improves test accuracy by 15%, enhancing competitive positioning.
4Growth in precision medicine adoption
5Advancements in AI for genomic analysis
6Adoption rates of precision medicine in oncology
7Partnerships with pharmaceutical companies for drug development
8Regulatory approvals for new genomic tests

FY2025 Snapshot

Revenue: $70M
Rev. Growth: -17.7%
Gross Margin: 22.7%
Op. Margin: -126%
Net Margin: -117%
Net Income: $-81M
NI Growth: +0.0%
EPS: $-0.91
1Y Return: +259%

PSNL Chart

My Notes

"Our focus on precision medicine is driving transformative partnerships that will redefine cancer treatment."
Moat: Personalis has a strong moat due to its proprietary technology and extensive genomic database…
growth - Investors are likely attracted to the potential for rapid expansion in the precision medicine market.
Interest rates affect the cost of capital for funding R&D and operational expenses, potentially impacting growth investments.
Watch on earnings: Number of genomic tests processed, Revenue growth rate, Partnership agreements.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $81M to $110M as recent partnership with a leading pharmaceutical company to develop a new genomic test for cancer treatment could.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.